A Study of BKM120 as a Single Agent in First Line Therapy in Advanced, Metastatic, or Recurrent Endometrial Cancers
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 12 Aug 2014
At a glance
- Drugs Buparlisib (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 29 Jul 2014 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov record.
- 23 Jan 2014 According to ClinicalTrials.gov record, Planned initiation date changed from 1 Dec 2013 to 1 May 2014.
- 23 Jan 2013 Status changed from not yet recruiting to discontinued, based on information in Novartis' Form 20-F (http://www.sec.gov/Archives/edgar/data/1114448/000104746913000377/a2212460z20-f.htm).